RC48 in Combination With AK104 and Bevacizumab in OCCC
Status:
RECRUITING
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University